ReviewCurrent pulmonology reports2022
Lung Cancer Screening: Review and 2021 Update.
Review in Current pulmonology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06473870 (Understanding Lung Cancer Related Risk Factors and Their Impact), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Understanding Lung Cancer Related Risk Factors and Their Impact
Who cites it
12 citing papers in PubMed.
- East-West Disparities in Lung Cancer Screening: Subsolid Nodule Prevalence, Interval Growth, and Decision-Making Analysis.Diagnostics (Basel, Switzerland) · 2026Review
- Correlation between CT growth patterns and invasiveness progression in neoplastic subcentimeter sub-solid nodules.Annals of medicine · 2025Article
- Improving lung cancer decision-making using a conversation tool (iDECIDE): a stepped wedge pragmatic clinical trial.Future oncology (London, England) · 2025Article
- Evaluation of Surgical Cases of Lung Cancer Admitted in Shiraz Referral Hospitals, Southern Iran in 2009-2022.Cancer reports (Hoboken, N.J.) · 2025Article
- Evaluating lung cancer risk factors in adults with interstitial lung disease.Lung cancer (Amsterdam, Netherlands) · 2025Article
- Diagnostic significance of the novel biomarker combination for early-stage non-small cell lung cancer detection: results of the blind clinical study.Frontiers in oncology · 2025Article
- Review
- Outcomes in Incidentally Versus Screening Detected Stage I Lung Cancer Surgery Patients.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024Article
- The Usefulness of Nanotechnology in Improving the Prognosis of Lung Cancer.Biomedicines · 2023Review
- Posttranslational modifications induce autoantibodies with risk prediction capability in patients with small cell lung cancer.Science translational medicine · 2023Article
- Single-cell immunophenotyping revealed the association of CD4+ central and CD4+ effector memory T cells linking exacerbating chronic obstructive pulmonary disease and NSCLC.Frontiers in immunology · 2023Article
- Investigation on the incidence and risk factors of lung cancer among Chinese hospital employees.Thoracic cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose of Review: Lung cancer screening with low-dose CT (LDCT) scans has been widely accepted within the last decade. Our knowledge and ability to implement screening has greatly increased because of significant research efforts and guidelines from multiple professional societies. The purpose of this review is to summarize some of the significant findings pertaining to lung cancer screening. Recent Findings: Screening with LDCT decreases lung cancer mortality in multiple studies. Use of validated risk prediction calculators can improve patient selection and screening efficiency. Shared decision making and smoking cessation counseling are essential screening components. Multidisciplinary involvement is required for the success of a screening program. Summary: Lung cancer screening is complex, and implementation of a successful program requires multidisciplinary expertise. Further prospective studies are required to determine optimal patient selection, screening intervals, and strategies to maximize benefit while further decreasing harms.'
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.